Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus
management.
Author(s): Powell J(1), Miller SA(1), Taylor JR(1).
Affiliation(s): Author information:
(1)From the University of Florida College of Pharmacy, Department of
Pharmacotherapy and Translational Research, Gainesville.
Publication date & source: 2015, South Med J. , 108(2):82-90
Type 2 diabetes mellitus continues to be a challenging disease to manage
successfully. Beyond the first-line option metformin, there are a number of
classes of medications from which to select. This article reviews the new
sodium-glucose cotransporter 2 inhibitors canagliflozin and dapagliflozin,
including their benefits, adverse effects, and potential place in therapy. Upon
review, the use of these medications has led to an A1c reduction between -0.37%
and -1.16%. These medications also have been shown to reduce A1c when used with
insulin. Some adverse effects were noted when using canagliflozin and
dapagliflozin, with the most frequent being urinary tract infections and genital
mycotic infections. We review the sodium-glucose cotransporter 2 inhibitors
approved by the US Food and Drug Administration and their potential roles in the
management of type 2 diabetes mellitus.
|